Thus, investigating CA-125 levels in this context may help to assess its possible value as a complementary, less-invasive screening tool for non-HPV-associated gynecological cancers, especially in remote areas where access to standard sanitary facilities for HPV-based screening technologies is limited. Here, MUC16 is linked to female reproductive organ cancer.